Revolution Medicines reported that its once-daily pill daraxonrasib nearly doubled survival for patients with previously treated metastatic pancreatic cancer, one of the deadliest cancers. In the Phase 3 RASolute 302 trial of about 500 patients, median overall survival reached 13.2 months versus 6.7 months for standard chemotherapy (hazard ratio 0.40, p<0.0001).
The oral drug is the first RAS inhibitor to extend survival in this setting. RAS mutations fuel more than 90% of pancreatic cancers but had long eluded treatment. Daraxonrasib worked whether or not a specific RAS mutation was detected, and patients reported less pain and better quality of life with fewer severe side effects than chemotherapy.
The results were published in the New England Journal of Medicine and presented in a late-breaking plenary session at the American Society of Clinical Oncology meeting in Chicago on May 31, 2026. The FDA has opened an expanded-access program and plans to expedite its review of the drug.